Drug Articles


  • [Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].

    The medicoeconomic issues of drug management of benign prostatic hyperplasia (BPH) are essential due to the aging population and the increasing number of therapeutic options. It is thus essential to assess the cost-effectiveness in order to define the most appropriate therapeutic strategies economically.

    Published December 16, 2015
  • Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation.

    To mirror guideline-adherence for pT1 bladder cancer treatment in Northern Germany.

    Overall, 111 patients with pT1 diagnosis were treated at 4 institutions. Guideline-adherence was defined as repeat resection, instillation, and quarterly cystoscopy.

    Published September 25, 2018
  • Lower Urinary Tract Symptoms: What's New in Medical Treatment?

    Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS).

    To review emerging evidence in the medical treatment of LUTS.

    An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS.

    Published April 22, 2018
  • Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

    Overactive bladder syndrome (OAB) is a prevalent disorder with a significant impact on quality of life. Despite this high prevalence, there is significant underdiagnosis and undertreatment due to several barriers, including embarrassment, poor communication and low patient adherence.

    Published April 28, 2018
  • Radium 223 dichloride for prostate cancer treatment.

    Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10 years. Among them, radium-223 dichloride (Xofigo(®)) is a radioactive isotope that induces irreversible DNA double-strand breaks and consequently tumor cell death.

    Published October 2, 2017
  • The impact of the global BCG shortage on treatment patterns: population-based data.

    An international shortage of Intravesical Bacillus Calmette-Guérin (BCG) therapy has considerably affected clinical practice patterns for non-muscle invasive bladder cancer. We aimed to review the trends of BCG therapy in Australia between April 2006 and 2016 using Pharmaceutical Benefits Australia data.

    Published October 31, 2017